Corvus Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and six months ended June 30, 2023. Corvus is a clinical-stage biopharmaceutical company developing oncology and immune-modulating drug candidates. It has not generated product revenue and reports one operating segment.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $4.0 million | $4.9 million | $8.6 million | $10.0 million |
| General and administrative expense | $1.7 million | $2.1 million | $3.6 million | $4.4 million |
| Net loss | $6.5 million | $8.4 million | $14.4 million | $16.7 million |
| Net loss per share, basic and diluted | $0.14 | $0.18 | $0.31 | $0.36 |
| Cash used in operating activities | Not separately provided for the quarter | $13.3 million | $12.5 million |
As of June 30, 2023, cash and cash equivalents were $7.7 million and marketable securities were $29.4 million, totaling $37.0 million. Total assets were $58.0 million, total liabilities $8.6 million, and stockholders’ equity $49.5 million. The filing reports no material interest-bearing debt; lease liabilities totaled approximately $2.0 million. Operating margins are not meaningful because the company has no revenue.
Accumulated deficit was $322.1 million. The company raised $7.5 million net through its at-the-market (ATM) offering during the six months, issuing 2,329,851 shares; $82.3 million remained available under the $90 million program at quarter-end.
Material changes versus the prior comparable period
- Q2 operating expenses decreased $1.4 million year over year, with R&D down $1.0 million and G&A down $0.4 million. Six-month operating expenses declined $2.2 million.
- Net loss narrowed by $1.9 million in Q2 and $2.3 million for the six-month period. Higher interest income partly offset operating costs; the six-month loss from Angel Pharmaceuticals increased by $0.4 million.
- R&D spending shifted among programs: six-month soquelitinib costs increased $1.6 million, while mupadolimab costs declined $2.8 million as Corvus paused its own development prioritization. Ciforadenant costs decreased $0.4 million.
- Cash, cash equivalents and marketable securities fell from $42.3 million at December 31, 2022 to $37.0 million at June 30, 2023. Operating cash use was higher than in the first half of 2022; ATM proceeds partly supported funding.
Outlook, commentary and key risks
- Management believes existing cash, cash equivalents and short-term marketable securities will fund planned operations for at least 12 months from issuance of the financial statements. However, Corvus says current resources are insufficient to fund all ongoing and planned programs through commercialization and expects to need additional financing. Future equity financing may dilute shareholders; debt or partnerships could impose restrictions or require relinquishing rights.
- Soquelitinib: Enrollment in the Phase 1/1b T-cell lymphoma trial continued. As of May 18, 2023, the 200 mg cohort included 30 patients, 20 evaluable for response; the company reported 3 complete and 3 partial responses. Among patients with absolute lymphocyte count above 900, 6 of 14 had objective responses and 12 of 14 had disease control; no objective responses were reported among 6 patients below that threshold. These are preliminary clinical findings, not confirmatory evidence. Corvus requested an FDA meeting to discuss a registrational Phase 3 trial and anticipated the meeting in Q3 2023. A solid-tumor Phase 1 trial was planned for the first half of 2024.
- Ciforadenant: The Phase 1b safety portion of a combination study in metastatic renal cell cancer was fully enrolled, and enrollment in Phase 2 was underway. Interim data were anticipated before year-end 2023.
- Mupadolimab: Corvus was prioritizing its other lead candidates before initiating a potential Phase 2 trial; Angel Pharmaceuticals continued a Phase 1 study in China.
- Primary risks include clinical-trial failure or delay, uncertain regulatory approval, patient-enrollment and safety issues, reliance on third-party manufacturers and CROs, competition, intellectual-property and licensing risks, and limited access to additional capital. Angel’s cash is not available to Corvus; Corvus owns approximately 49.7% of Angel.
- No material legal proceedings were reported. Management concluded disclosure controls were effective as of June 30, 2023, and reported no material change in internal control over financial reporting.
Investor verification priorities
- Track cash burn, ATM sales and dilution, and whether additional financing is obtained on acceptable terms.
- Verify clinical updates against complete, later-stage data, including the durability and safety of soquelitinib responses and the validity of the reported lymphocyte-count biomarker.
- Confirm outcomes and timing of the FDA discussion and whether a Phase 3 design and funding plan are established.
- Check ciforadenant trial progress and any interim results, and clarify the timing and scope of Corvus’s own mupadolimab development.
- Monitor Angel Pharmaceuticals’ development progress, funding and collaboration obligations, while distinguishing its resources from Corvus’s available liquidity.